Drug Profile
Aficamten - Cytokinetics
Alternative Names: CK 3773274; CK-274Latest Information Update: 10 Apr 2024
Price :
$50
*
At a glance
- Originator Cytokinetics
- Developer Cytokinetics; Ji Xing Pharmaceuticals
- Class Amides; Cardiovascular therapies; Heart failure therapies; Indenes; Oxadiazoles; Pyrazoles; Small molecules
- Mechanism of Action Cardiac myosin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hypertrophic cardiomyopathy
Most Recent Events
- 05 Apr 2024 Updated efficacy data from the phase II FOREST-HCM trial in Hypertrophic cardiomyopathy released by Cytokinetics
- 27 Feb 2024 Cytokinetics announces intention to submit Marketing Authorization Application (MAA) to EMA for Hypertrophic cardiomyopathy in the fourth quarter of 2024
- 27 Feb 2024 Cytokinetics announces intention to submit New Drug Application (NDA) to the US FDA for Hypertrophic cardiomyopathy in the third quarter of 2024